Skip to main content
    T

    Transcode Therapeutics Inc (RNAZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.35
    +0.03 (+2.27%)

    Market Cap: $22.35M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Transcode Therapeutics Inc (RNAZ) Earnings: Report Dates and Results

    Updated Aug 14, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Jun 30, 2026, Transcode Therapeutics reported EPS of -$7.17. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    43%(6/14)
    Avg Surprise
    -44.01%

    Next Report

    RNAZ's next report is not on the earnings calendar yet.

    Earnings History

    Of the 14 quarters below that had an estimate, RNAZ beat 6, missed 7 and matched 1. The widest gap in the table came in the quarter ended Sep 30, 2025, when EPS landed 470.59% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Jun 30, 2026-$7.17N/AN/AN/AN/AN/AN/AN/AAug 14, 2026
    Mar 31, 2026-$21.28N/AN/AN/AN/AN/AN/AN/AApr 15, 2026
    Dec 31, 2025-$16.42N/AN/AN/AN/AN/AN/AN/AFeb 25, 2026
    Sep 30, 2025-$5.82-$1.02N/A-470.59%MissN/AN/AN/ANov 14, 2025
    Jun 30, 2025-$5.13-$1.64N/A-212.80%MissN/A1N/AAug 14, 2025
    Mar 31, 2025-$1,286.15-$89.88N/AN/AN/AN/AN/A0 up, 1 downMay 14, 2025
    Dec 31, 2024-$1,286.15-$89.88N/AN/AN/AN/A11 up, 0 downMar 28, 2025
    Sep 30, 2024-$147.84-$452.76N/A+67.35%BeatN/A11 up, 0 downNov 14, 2024
    Jun 30, 2024-$27,350.42-$21,436.81N/A-27.59%MissN/A10 up, 0 downAug 14, 2024
    Mar 31, 2024-$600.60-$25,872.02N/A+97.68%BeatN/A10 up, 0 downMay 15, 2024
    Dec 31, 2023-$627.33-$356.40N/A-76.02%MissN/A10 up, 0 downMar 29, 2024
    Sep 30, 2023-$62,092.84-$55,440.03N/A-12.00%MissN/A10 up, 0 downNov 14, 2023
    Jun 30, 2023-$121,598.47-$125,294.48N/A+2.95%BeatN/A10 up, 0 downAug 14, 2023
    Mar 31, 2023-$0.38-$0.38N/A0.00%In lineN/AN/A0 up, 0 downMay 15, 2023
    Dec 31, 2022-$288,288.17-$280,896.17N/A-2.63%MissN/A10 up, 0 downMar 30, 2023
    Sep 30, 2022-$243,936.15-$295,680.18N/A+17.50%BeatN/A10 up, 0 downNov 14, 2022
    Jun 30, 2022-$266,112.16-$221,760.13N/A-20.00%Miss-52178954.9%N/A0 up, 0 downAug 15, 2022
    Mar 31, 2022-$0.22-$0.25N/A+12.00%BeatN/AN/A0 up, 0 downMay 16, 2022
    Dec 31, 2021-$170,016.10-$184,800.11N/A+8.00%BeatN/A10 up, 0 downMar 31, 2022
    Sep 30, 2021-$0.20N/AN/AN/AN/AN/AN/AN/ANov 15, 2021
    Jun 30, 2021$0.51N/AN/AN/AN/AN/AN/AN/AJul 9, 2021
    Last 21 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1,313.52, after -$29,385.01 the year before. It was -$170,015.79 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1,313.52N/A
    Dec 31, 2024-$29,385.01N/A
    Dec 31, 2023-$184,319.02N/A
    Dec 31, 2022-$798,336.70N/A
    Dec 31, 2021-$170,015.79N/A

    Frequently Asked Questions About RNAZ

    How often does RNAZ beat earnings estimates?

    Transcode Therapeutics beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of -78.88%.